HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Liver transplantation using hepatitis B core antibody-positive grafts: review and university of Tokyo experience.

Abstract
Hepatitis B surface antigen-negative and hepatitis B core antibody-positive grafts were considered unsuitable for transplantation. The number of potential recipients for liver transplantation now exceeds that of potential donor organs, which has led us to reevaluate the feasibility of these grafts. Several strategies involving prophylactic administration of hepatitis B immunoglobulin and/or lamivudine to transplant recipients have been proposed. At the University of Tokyo, we have continued to use hepatitis B immunoglobulin monoprophylaxis with zero recurrence. In this article we report our experience with the use of hepatitis B surface antigen-negative/hepatitis B core antibody-positive grafts with hepatitis B immunoglobulin monotherapy. We conducted a review of the literature regarding the feasibility of these grafts to reconfirm optimal prophylactic strategies for preventing de novo hepatitis B virus infection in transplant recipients.
AuthorsNobuyuki Takemura, Yasuhiko Sugawara, Sumihito Tamura, Masatoshi Makuuchi
JournalDigestive diseases and sciences (Dig Dis Sci) Vol. 52 Issue 10 Pg. 2472-7 (Oct 2007) ISSN: 0163-2116 [Print] United States
PMID17805972 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
Chemical References
  • Hepatitis B Antibodies
  • Hepatitis B Surface Antigens
  • Immunoglobulins
  • Reverse Transcriptase Inhibitors
  • Lamivudine
  • hepatitis B hyperimmune globulin
Topics
  • Disease Transmission, Infectious (prevention & control)
  • Hepatitis B (immunology, transmission, virology)
  • Hepatitis B Antibodies (immunology)
  • Hepatitis B Surface Antigens (immunology)
  • Hepatitis B virus (immunology)
  • Humans
  • Immunization, Passive (methods)
  • Immunoglobulins (therapeutic use)
  • Japan
  • Lamivudine (therapeutic use)
  • Liver Transplantation (methods)
  • Reverse Transcriptase Inhibitors (therapeutic use)
  • Risk Factors
  • Tissue Donors
  • Universities

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: